Clinical Trial Update: A Phase 2 Study to Evaluate the Safety and Efficacy of LOU064 in Patients With Moderate to Severe Sjögren's Syndrome [Phase 2]

View source ↗

Summary

A Phase 2 study evaluating safety and efficacy of LOU064 in patients with Sjögren's syndrome was terminated with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Sjögren Syndrome

Drugs mentioned

• LOU064

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Sjögren Syndrome | Phase 2 | Status: TERMINATED | Results posted: 2022-12-20